We train early stage biomedical project teams in how to commercialize their innovations
The C3i program is designed to provide innovators with the specialized business framework and essential tools for successful translation of biomedical technologies from lab to market.
The C3i Program is based on the Coulter Commercialization Process, an approach to biomedical research translation developed and continuously refined by the Wallace H. Coulter Foundation in collaboration with its academic partners across the country. Since 2005, the Foundation has supported more than 450 interdisciplinary teams of scientists and engineers to bring the latest biomedical innovations to the market. To-date, 104 projects have raised $2.7 billion in venture capital, 47 projects have been licensed to industry partners, and dozens more have received SBIR support. Most importantly, these efforts have given risen to 35 products in the market improving the lives of millions of patients around the world.
Frank has 35 years of medical device experience in the cardiovascular, orthopedic, and aesthetic market segments. He has been the founder of numerous medical device start-ups. Frank is also Co-founder of Gore Range Capital, LLC a venture firm focused on early stage medical technology commercialization.
Rachael is a recognized as a leader with a demonstrated track record of commercializing early-stage technology out of universities. She has provided expert advice on medical technology investment to early stage funds and angel investors. She has developed a very extensive network of early stage CEOs and funding sources.
Shahram is a life science investor and entrepreneur, is a Venture Partner with BioAdvance,.. He is a Board Member for Infrascan, Inc., Optofluidics, Inc., WellTrackOne Inc., HealthQX , Enzium, Inc., and Cohero Health Inc. Shahram is the James Wei Visiting Professor of Entrepreneurship, Princeton University. Previously, Dr. Hejazi was President of Kodak’s life science.
Manuel is an expert in medical technology evaluation and commercialization. Worked for McKinsey& Co. in M&A and developing growth strategies. He worked for Baxter Healthcare, Edwards Lifesciences, and CR Bard in a diverse set of industry leadership roles including product development, assessing new markets, strategy, operations, and M&A.
Rob is an entrepreneurial executive with demonstrated expertise in technology, medicine and regulatory affairs. Specialties: clinical engineering, diagnostic imaging, minimally invasive surgery, non-invasive surgery, QSR/MDD, medical devices, clinical trials, team building, image-guided surgery, neurostimulation, robotics, IDE, PMA, Class II Devices, Class III Devices, thermal ablation, focused ultrasound, insulin delivery.
Rifat serves as CEO of Midway Pharmaceuticals, Managing Partner of RxMP Therapeutics and Mobius Innovations, Director of Atrin Pharmaceuticals and Midway Animal Health. As Founder and CSO of Cell Pathways, he raised over $140M and took the company public on NASDAQ. He has been featured in Time, Business Week, Forbes and Dateline NBC, has authored over 110 academic publications, and is an inventor on 150+ issued patents. Rifat received his BA from the Johns Hopkins University and MD from University of Wisconsin. He trained in GI at the University of Chicago.
Donna See is a Vice President at Allied Minds, a publicly-traded venture capital firm (London Stock Exchange: ALM) specializing in U.S. university and federal lab technology commercialization. As a member of the investment team, Donna brings more than 14 years of experience in academic technology transfer, public-private partnerships, and early-stage technology development. She most recently served as Director of Licensing and Director of Strategic Initiatives for Columbia Technology Ventures, an internationally recognized leader in academic tech transfer.
Global technology and medical industry executive with a background in general management, operations and marketing. Demonstrated commercialization skill in a variety of technologies and applications including urology, surgery, orthopedics, oncology, imaging, lasers and software. Proven ability to conceptualize and manage complex solutions to address business, customer and product development needs.
Elias is president and founder of Biocomx a non-for-profit organization dedicated to train biomedical innovators in commercialization. At the Coulter Foundation as VP of Technology oversees the Translational Partnership Programs at 16 universities. As Senior VP of Beckman Coulter, he was in charge of worldwide commercial operations, and previously was president of the biomedical division. For Coulter Corporation managed companies in Japan, France, Belgium and Latin America.
Our group of project managers are experienced professionals that as Coulter Program Directors oversee the Coulter Translational Partnership Programs at their universities. These programs have funded over 450 projects, 104 of them have raised over $2.8 billion in funding, licensed 48 projects to industry received more than $400 million in governmental funding and launched 35 products to market improving the lives of millions of patients worldwide.
Coulter Program Manager at the University of Pittsburgh. BS in Electrical Engineering, MS Biomedical Engineering and MBA.
Coulter Program Manager at the University of Missouri. BS in Engineering Instrumentation and Control and PhD in Biomedical Engineering.
Coulter Program Director at Drexel University. BS in Biology and PhD in Molecular and Cellular Biology.
Coulter Program Director at Georgia Tech – Emory. BS in Biomedical Engineering and MS in Biomedical Innovation and Development.
Coulter Program Manager at Johns Hopkins University. BS Engineering Physics and PhD in Biophysics.
BS Biomedical Engineering, PhD Bioengineering and MBA.
Associate Director at Emory/GT Coulter Translational Fund. Doctor of Physical Therapy and MBA.
Manager at Biocomx. BS in Biomedical Engineering, MS in Macromolecular Science and MS in Material Science.